|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||3.15 - 3.45|
|52 Week Range||2.73 - 5.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.00|
NEW YORK , April 5, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin , Chief Executive Officer, will present at ...
Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, and Bio-Nucleonics, licensor of Strontium 89 Chloride, announce submission of a regulatory filing to the FDA for the approval of a new manufacturing facility. Upon approval by the FDA, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP (Strontium-89) in accordance with cGMP. Strontium-89 is a non-opioid injectable radiopharmaceutical to relieve cancer bone pain in patients with painful skeletal metastases.
NEW YORK , March 9, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin , Chief Executive Officer will present at the ...
OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for ...
NEW YORK, NY / ACCESSWIRE / February 2 2 , 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of CytoDyn Inc. (OTCQB: CYDY ) and Q Biomed Inc. (OTCQB: QBIO ...
Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to welcome Dr. Rick Panicucci as an independent member on its board of Directors. Dr. Rick Panicucci is the Vice President of Pharmaceutical Development at STA Pharmaceutical Co. Ltd. (A WuXi AppTec Company). Rick has been providing formulation and development support to Mannin Research on Man01, our glaucoma drug candidate.
Q BioMed Inc. (QBIO), is pleased to announce an exclusive option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will evaluate the feasibility and usability of GDF-15, a novel biomarker for monitoring glaucoma, as a companion diagnostic to the MAN-01 small molecule currently being optimized for the topical treatment of glaucoma.
Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce the closing of its previously announced public offering of an aggregate of 1,711,875 units consisting of one common and share and one warrant at a public offering price of $3.20 per unit for gross proceeds of $5.48 million. Roth Capital Partners acted as lead placement agent and CIM Securities acted as co-lead placement agent for the offering.
Q BioMed Inc. (QBIO) ("Q BioMed" or the "Company"), a commercial stage biotechnology acceleration development company is pleased to announce pricing of a public offering of an aggregate of 1,711,875 shares of common stock of the Company, together with warrants to purchase up to 1,711,875 shares of common stock of the Company, at a public offering price of $3.20 per share and associated warrant. The gross proceeds from the offering are expected to be approximately $5.5 million, before deducting placement agent fees and other estimated offering expenses. Roth Capital Partners is acting as lead placement agent and CIM Securities is acting as co-lead placement agent for the offering.
NEW YORK , January 3, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company announced today that Denis Corin , Chief Executive Officer, will present at the Biotech Showcase(™) ...
NEW YORK, Dec. 21, 2017 /PRNewswire/ -- Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to provide this year end update to its shareholders. The Company also ends the year with a clean balance sheet, having settled all outstanding debt and is poised for a very productive a catalyst-rich year in 2018. Strontium-89 is a U.S. Food and Drug Administration approved drug for pain palliation in bone metastases, primarily from breast, prostate and lung cancers.
Q BioMed Inc. (QBIO), a biotechnology acceleration Company, announced today that all convertible notes and loans have been settled in full, including the $4 million of convertible notes that had been issued pursuant to a Securities Purchase Agreement dated November 29, 2016. The company ended its 2017 financial year with no outstanding loans or convertible debt. This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, announced today that Dr. Helen Tager-Flusberg from Boston University has joined its advisory committee for QBM-001, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders. Dr. Tager-Flusberg has provided the protocol for capturing the primary endpoint of the planned trial for QBM-001.
Q BioMed Inc. (QBIO) congratulates our collaborative research partner and licensor, Mannin Research Inc., on receiving R&D funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to initiate work on a Tie2-activating biologic for the treatment of glaucoma. Q BioMed has licensed the Mannin Tie2 technology, and is collaboratively developing the Tie2 platform for glaucoma, and other indications. This new biologic would be an additional product to the Mannin Tie2 pipeline.
Q BioMed Inc. (QBIO), a biotechnology acceleration Company, announced today that their funding partner Yorkville Advisors have agreed to extend the maturity date on the $2M balance of their convertible note by one year to November 30 2018. Dens Corin, CEO of QBioMed Inc. said, "Our relationship with Yorkville Advisors and their team has been very positive.
Q BioMed Inc. (QBIO), a biotechnology acceleration Company, announced today the launch of http://www.PainFreeCancer.com. In the body, Strontium-89 acts similar to calcium and is preferentially taken up in osteoblastic tissue selectively localizing in bone mineral. Strontium Chloride Sr89 Injection, USP can be used in combination with other therapeutic drugs.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder. "The goal of our collaboration with Sphaera Pharma is to put the patient first, especially since QBM-001 targets a rare subset of toddlers that become non- or minimally verbal for the rest of their lives," said Denis Corin, CEO of Q BioMed. Sphaera Pharma will employ its proprietary and patented platform to produce a novel analog that aims to reduce or eliminate potential side effects and can reduce the amount of product a toddler needs to take on a daily basis.
Q BioMed Inc. (QBIO) is pleased to announce the closing of a $3,050,390 equity financing. The financing with a small group of accredited investors provides the necessary capital to meet near term milestones and catalysts in its most advanced product portfolio assets, including the commercialization of Strontium Chloride 89, multiple IND enabling studies, CMC manufacturing and at least one IND filing.
NEW YORK , July 10, 2017 /PRNewswire/ -- Q BioMed Inc. (QBIO) will be featured on CEO Clips airing on Bloomberg Television July 10 through 14th . CEO Clips, profiles some of the most innovative publicly ...
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2017) - Darin Corin, CEO of Q BioMed, talks about the future plans for the company which includes a new drug application.If you cannot view the video above, please visit:http://www.b-tv.com/q-biomed-ceo-clip/Q BioMed Inc. is being featured on CBC's Documentary Channel July 10 -23, Monday through Friday, throughout the day and evenings. Q BioMed Inc.(OTCQB: QBIO) :Q BioMed Inc. is a biomedical acceleration and development company. We are dedicated ...
NEW YORK, NY / ACCESSWIRE / July 7, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued ...
Q BioMed Inc. (QBIO), a biotechnology acceleration company, announced today that Christopher Manuele will join the Strontium 89 Chloride commercialization team. Mr. Manuele is a results-oriented, innovative executive with thirty-five years of comprehensive US and International expertise in nuclear medicine and medical isotope production. Before his retirement in 2008, Mr. Manuele served as General Manager - Global Nuclear Medicine Supply Chain for GE Healthcare, and General Manager - Oncura, GE's global I-125 brachytherapy seeds business.
Q BioMed Inc. (QBIO), is very pleased to announce their entry into a final license agreement with The Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB). Under the agreement QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer. In animal models, the compound, called uttrocide B, was shown to be 10 times more cytotoxic to HepG2 liver cancer cells than the only drug currently on the market for the condition.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, announced today that it will be a featured presenter at the 6th Annual Marcum MicroCap Conference on Thursday, June 15, 2017 in New York City at the Grand Hyatt Hotel. The Company's presentation by Denis Corin, Q BioMed Inc. CEO, is scheduled to begin at 9:30a.m ET on Thursday June 15th in the Julliard Room. Since its launch in 2012, this event has become a nationally recognized forum for publicly traded companies with less than $500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities.
Q BioMed Inc. (QBIO), and executives from its advanced technology partner Bio-Nucleonics Inc. will attend the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting that is being held in Denver, Colorado June 10 - 14, 2017. The meeting provides an ideal location to meet with collaborators, vendors and partners working on the recently announced commercialization of Strontium-89 Chloride (Sr89). Sr89 Injection USP is a non-opioid analgesic indicated for the relief of bone pain in patients with painful skeletal cancer metastases.